Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04368507
Recruitment Status : Recruiting
First Posted : April 29, 2020
Last Update Posted : April 29, 2020
Sponsor:
Collaborator:
Yooyoung Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
National OncoVenture

Brief Summary:
To evaluate the safety, tolerability, pharmacokinetics and antitumor activity of YYB101 with Irinotecan, patients who are metastatic or recurrent Colorectal Cancer Patients.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Metastatic Colorectal Cancer Recurrent Drug: YYB101 Phase 1 Phase 2

Detailed Description:
Metastatic or recurrent colorectal cancer patients will be enrolled to evaluate the safety, tolerability, pharmacokinetics, and efficacy of YYB101 in combination with irinotecan. In Phase 1b, YYB101 20 mg/kg in combination with irinotecan 150 mg/m2 will be administered as a dose level 0, and the safety and pharmacokinetic assessments will be performed based on the DLT after a 4-week treatment period. If no DLT occurs during the 4-week observation period, dosing will be continued every 2 weeks until progressive disease (PD) or unacceptable toxicity occurs. After completion of Phase 1b, the SRC will determine the RP2D of YYB101 and irinotecan, and Phase 2a will be initiated. Stage 2 will proceed when unconfirmed response is observed in one or more subjects out of 10 subjects evaluable for tumor in Phase 2a Stage 1 which includes the RP2D dose cohort in Phase 1b.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b/2a Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101, Hepatocyte Growth Factor (HGF)-Neutralizing Humanized Monoclonal Antibody (Mab) in Combination With Irinotecan in Metastatic or Recurrent Colorectal Cancer Patients
Actual Study Start Date : August 9, 2019
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : May 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: YYB101+Irinotecan
  1. b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks
  2. a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks
Drug: YYB101
  1. b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity
  2. a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity




Primary Outcome Measures :
  1. 1b (Dose level 0) cohort: Safety, Tolerability of YYB101 by DLTs and MTD [ Time Frame: 28 days ]
    DLTs and MTD

  2. 2a cohort: Safety, Tolerability of YYB101 by ORR [ Time Frame: By 12 months after enrollment of the last subject ]
    ORR


Secondary Outcome Measures :
  1. 1b (Dose level 0) cohort [ Time Frame: By 12 months after enrollment of the last subject ]
    Safety and tolerability (MTD/RP2D based by DLT, Incidence of AEs that result in discontinuation and dose reduction of YYB101, Clinical laboratory abnormalities that result in discontinuation and dose reduction of YYB101, Vital sign that result in discontinuation and dose reduction of YYB101, Anti-YYB101 antibody that result in discontinuation and dose reduction of YYB101)

  2. 1b (Dose level 0) cohort [ Time Frame: By 12 months after enrollment of the last subject ]
    Pharmacokinetics: Area under the plasma concentration versus time curve (AUC)

  3. 1b (Dose level 0) cohort [ Time Frame: By 12 months after enrollment of the last subject ]
    Pharmacokinetics: Peak Plasma Concentration (Cmax)

  4. 1b (Dose level 0) cohort [ Time Frame: By 12 months after enrollment of the last subject ]
    Pharmacokinetics: Serum HGF Concentration profile

  5. 1b (Dose level 0) cohort [ Time Frame: By 12 months after enrollment of the last subject ]
    Antitumor activity of YYB101 and Irinotecan (Tumor response result evaluted by RECIST version 1.1)

  6. 2a cohort [ Time Frame: By 12 months after enrollment of the last subject ]
    Progression-free survival (PFS) will be measured using RECIST version 1.1

  7. 2a cohort [ Time Frame: By 12 months after enrollment of the last subject ]
    Disease Control Rate (DCR) will be measured using RECIST version 1.1

  8. 2a cohort [ Time Frame: By 12 months after enrollment of the last subject ]
    Duration Of Response (DOR) will be measured using RECIST version 1.1

  9. 2a cohort [ Time Frame: By 12 months after enrollment of the last subject ]
    Overall Survival (OS) will be measured using RECIST version 1.1

  10. 2a cohort [ Time Frame: By 12 months after enrollment of the last subject ]
    Safety profile (Incidence of AEs that result in discontinuation and dose reduction of YYB101, Clinical laboratory abnormalities that result in discontinuation and dose reduction of YYB101, Vital sign that result in discontinuation and dose reduction of YYB101, Anti-YYB101 antibody that result in discontinuation and dose reduction of YYB101)

  11. 2a cohort [ Time Frame: By 12 months after enrollment of the last subject ]
    Pharmacokinetics: Area under the plasma concentration versus time curve (AUC)

  12. 2a cohort [ Time Frame: By 12 months after enrollment of the last subject ]
    Pharmacokinetics: Peak Plasma Concentration (Cmax)

  13. 2a cohort [ Time Frame: By 12 months after enrollment of the last subject ]
    Pharmacokinetics: Serum HGF Concentration profile [only stage 1 subject]



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female patients aged ≥ 19 years
  2. Patients with histologically confirmed metastatic or recurrent colorectal cancer

    • Patients who progressed after standard anticancer treatment including existing fluoropyrimidine, oxaliplatin, and irinotecan
    • Patients who received anticancer treatment including irinotecan for at least 6 weeks, with progression confirmed radiologically while on anticancer treatment or within 6 months (24 weeks) after completion of anticancer treatment
    • Adjuvant therapy is acknowledged as an anticancer therapy, if PD is confirmed within 6 months (24 weeks) after the last dose
    • Patients who are unable to undergo radical resection 3) Patients with Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 4) Patients with life expectancy of at least 12 weeks 5) Patients with confirmed adequate hematologic, renal and hepatic function based on the following criteria:
    • ANC ≥ 1,500/μL (without granulocyte colony-stimulating factor (G-CSF) administration within 2 weeks prior to baseline)
    • Platelet ≥ 100,000/μL (without transfusion within 2 weeks prior to baseline)
    • Hemoglobin ≥ 9 g/dL (without transfusion within 4 weeks prior to baseline)
    • Serum creatinine ≤ 1.5 mg/dL or estimated glomerular filtration rate (eGFR) (or GFR) ≥ 60 mL/min/1.73 m2
    • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 X upper limit of normal (ULN) (AST and ALT ≤ 5 X ULN for subjects with confirmed hepatic metastases)
    • Total bilirubin ≤ 1.5 X ULN
    • Prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 X ULN
    • Urine protein to creatinine ratio (UPC) < 1.0 0 (g/g)a a UPC will be conducted only when urine dipstick protein level is ≥ 1 positive (+).

6. Patients with a measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 7. Patients who voluntarily agree to participate in the study and sign the informed consent form

Exclusion Criteria:

  1. Patients with hematologic malignancy including lymphoma
  2. Patients who received chemotherapy, biological therapy, immunotherapy (including immune checkpoint inhibitors), or radiotherapy within 4 weeks prior to baseline for the treatment of metastatic or recurrent colorectal cancer (Participation is not allowed if nitrosoureas or mitomycin is administered within 6 weeks prior to baseline or if biological target antibody is administered within 8 weeks prior to baseline)
  3. Patients with a history of primary malignancy other than colorectal cancer. However, the patients are permitted to participate if:

    • They have not received any treatment for the tumor or are disease-free for at least 5 years (For papillary carcinoma of thyroid, participation in the study is allowed even if it has not been more than 5 years after radical resection.)
    • At least 1 year has passed since complete resection of basal/squamous cell carcinoma of the skin or successful treatment of cervical carcinoma in situ
  4. Patients with symptomatic central nervous system metastases (except for patients who have discontinued systemic corticosteroid treatment at least 4 weeks prior to baseline and are neurologically stable for at least 4 weeks)
  5. Patients with the following medical or surgical/procedural history

    • Deep vein thrombosis (DVT) or pulmonary embolism (PE) within 1 year prior to baseline
    • History of infection with cytomegalovirus (CMV) or Epstein-Barr virus (EBV) within 6 months (24 weeks) prior to baseline
    • History of acute coronary syndrome (unstable angina or myocardial infarction) within 6 months (24 weeks) prior to baseline
    • Serious cerebrovascular disease such as stroke within 6 months (24 weeks) prior to baseline
    • Major surgery that requires general anesthesia or a ventilation assist within 4 weeks prior to baseline (within 2 weeks for video-assisted thoracoscopic surgery [VATS] or open-and-closed [ONC] surgery)
  6. Patients with any of the following diseases:

    • New York Heart Association (NYHA) class III or IV heart failure
    • Uncontrolled hypertension (SBP > 160 mmHg or DBP > 90 mmHg despite drug treatments)
    • Clinically significant cardiovascular abnormalities as determined by the investigator (e.g., left ventricular ejection fraction [LVEF] < 50%, clinically significant abnormal cardiac wall or myocardial injury, or uncontrolled cardiac arrhythmias)
    • Known positive human immunodeficiency virus (HIV)
    • Severe infection requiring systemic antibiotics, antivirals, etc. or other uncontrolled acute active infectious diseases
    • Chronic inflammatory bowel disease
    • Severe enteroplegia or ileus requiring intervention
    • Pneumonitis or pulmonary fibrosis
    • Large amount of ascites or pleural fluid
    • Diarrhea (watery stool)
  7. Patients requiring continued treatment with systemic corticosteroids
  8. Patients on antithrombotic agents (patients on low dose aspirin of < 325 mg for inhibition of platelet aggregation is allowed to participate) or with a predisposition to bleeding, large amount of hemoptysis, gastrointestinal hemorrhage or peptic ulcers
  9. Patients with a history of severe drug hypersensitivity or hypersensitivity to class of drugs similar to the study drug/concurrent medications
  10. Pregnant or breast-feeding women
  11. Women of childbearing potential and men who are unwilling to remain abstinent or use appropriate methods of contraception during the study and for at least 5 months (20 weeks) following the end of treatment
  12. Patients who received other investigational product or used any investigational device within 4 weeks prior to baseline
  13. Patients considered ineligible to participate in the clinical study according to the investigator's judgement for other reasons

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04368507


Contacts
Layout table for location contacts
Contact: Jeeyun Lee, Ph.D 82-2-3419-1779 jyun.lee@samsung.com

Locations
Layout table for location information
Korea, Republic of
National Cancer Center Recruiting
Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769
Samsung Medical Center Recruiting
Gangnam-gu, Seoul, Korea, Republic of, 135-710
Seoul ST. Mary's Hospital Recruiting
Gangnam-gu, Seoul, 222, Korea, Republic of
Sponsors and Collaborators
National OncoVenture
Yooyoung Pharmaceutical Co., Ltd.
Investigators
Layout table for investigator information
Study Director: Hoonkyo Kim, Ph.D National OncoVenture/National Cancer Center
Study Director: Garam Im National OncoVenture/National Cancer Center
Layout table for additonal information
Responsible Party: National OncoVenture
ClinicalTrials.gov Identifier: NCT04368507    
Other Study ID Numbers: NOV110501-201
First Posted: April 29, 2020    Key Record Dates
Last Update Posted: April 29, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases